MMP2 and cancer: However, Ferucarbotran causes dose-dependent inhibition of osteogenic differentiation of human mesenchymal stem cells, cancels osteogenic differentiation at high concentrations, promotes cell migration, and activates signal molecules β-Catenin, cancer/testicular antigen, SSX and matrix metalloproteinase 2 (MMP2) [21].